Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each case with a grant date of February 1, 2024, as equity inducement awards under the terms of the company’s 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (MDGL)
- Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
- Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
- Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
- Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
- Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra